Rigel Pharmaceuticals' (RIGL) Tavalisse, launched in mid-2018, is experiencing sales growth but competitors exist that could potentially reduce peak sales. RIGL's partnered pipeline provides a source of potentially good news to offset any bad news regarding advances from RIGL's competitors. These competitors and collaborators are the focus of this article.
Figure 1: Numbers on the launch of Tavalisse. Source: RIGL corporate presentation.
Aclaris' ATI-501 and ATI-502
Aclaris Therapeutics (ACRS) is developing ATI-501 and ATI-502, which the company licensed from RIGL. Since I previously wrote about ATI-501 and ATI-502, ACRS has